This report was first published by Endpoints News. To see the original version, click here
Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a similar margin as Mounjaro achieved in its pivotal diabetes study.
The triple-G, which is called retatrutide, also produced 15.3% body weight loss at just over nine months. This combination of blood sugar-lowering and weight loss should make the drug appealing, if it reaches the market, Lilly’s president of cardiometabolic health Kenneth Custer told Endpoints News.
您已阅读12%（587字），剩余88%（4460字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。